{"DataElement":{"publicId":"2503796","version":"1","preferredName":"Residual Tumor Breslow Depth Measurement","preferredDefinition":"The measurement extent downward or inward of remaining tumor expressed using Breslow 's thickness: maximal thickness of a primary cutaneous melanoma measured in tissue sections from the top of the epidermal granular layer, or from the ulcer base (if the tumor is ulcerated), to the bottom of the tumor, with metastatic rates correlating closely with tumor thickness.","longName":"RES_TUM_BRES_MSRMT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2503794","version":"1","preferredName":"Residual Neoplasm Breslow Depth","preferredDefinition":"The extent downward or inward of remaining tumor expressed using Breslow 's thickness: maximal thickness of a primary cutaneous melanoma measured in tissue sections from the top of the epidermal granular layer, or from the ulcer base (if the tumor is ulcerated), to the bottom of the tumor, with metastatic rates correlating closely with tumor thickness.","longName":"RES_TUM_BRES_DEPTH","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2503791","version":"1","preferredName":"Residual Neoplasm","preferredDefinition":"Remaining or left behind.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C37895:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A85D824-42F4-4C72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-08","modifiedBy":"ONEDATA","dateModified":"2006-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2503792","version":"1","preferredName":"Breslow Depth","preferredDefinition":"Breslow 's thickness. maximal thickness of a primary cutaneous melanoma measured in tissue sections from the top of the epidermal granular layer, or from the ulcer base (if the tumor is ulcerated), to the bottom of the tumor; metastatic rates correlate closely with tumor thickness. (from On-line Medical Dictionary):Depth; extent downward or inward.","longName":"C25734:C25333","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breslow Thickness","conceptCode":"C25734","definition":"The measurement in millimeters of the vertical thickness of primary cutaneous melanoma.  Breslow thickness is measured from the granular layer of the epidermis, or the ulcer base (if ulcerated), to the deepest tumor cells.  It is used in staging of melanoma. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Depth","conceptCode":"C25333","definition":"The extent downward or inward; the perpendicular measurement from the surface downward to determine deepness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A85D824-4305-4C72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-08","modifiedBy":"ONEDATA","dateModified":"2006-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A85D824-4316-4C72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2186379","version":"1","preferredName":"Breslow Depth Measurement","preferredDefinition":"the thickness of the melanoma, also known as Breslow Thickness.","longName":"BRES_DEPTH_MSRMT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"6","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184312","version":"1","preferredName":"Measurement","preferredDefinition":"Measurement; the size or magnitude of something.","longName":"C25209","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurement","conceptCode":"C25209","definition":"Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"DB6C8AC6-1DB1-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"DWARZEL","dateModified":"2006-10-26","changeDescription":"Move to caBIG context as teh preferred Rep class for Measurement","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0C21CBA-DF0B-1377-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-03","modifiedBy":"CAMPBELB","dateModified":"2004-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812575","version":"1","longName":"AZCC 0210","context":"NCIP"},{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812205","version":"1","longName":"Arizona Cancer Center","context":"NCIP"},{"publicId":"2812607","version":"1","longName":"Arizona New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Breslow thickness of residual","type":"Preferred Question Text","description":"Breslow thickness of residual (if any)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"1A85E3BE-A2DA-4F5A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-08","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated to support Arizona Cancer Center adoption of C3D.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}